Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides

Bioconjugate Chemistry

Volumn 13, Issue 4, 2002, Pages 729-736

  Niesner, Uwe ^a   Halin, Cornelia ^a   Lozzi, Luisa ^b   Günthert, Maja ^a   Neri, Paolo ^b   Wunderli Allenspach, Heidi ^a   Zardi, Luciano ^c   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL PROLIFERATION; DISEASES; MAMMALS; MONOCLONAL ANTIBODIES; TUMORS;

ANTI-CANCER THERAPEUTICS; ANTIBODY-FRAGMENT; D-AMINO ACIDS; FUSION PROTEINS; HIV-TAT; HUMAN MONOCLONAL ANTIBODIES; PROPERTY; REPORTER PROTEIN; TUMOR MASS; TUMOR-TARGETING;

PEPTIDES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

CANCER ANTIBODY; DNA VACCINE; FIBRONECTIN; HYBRID PROTEIN; IMMUNOGLOBULIN FRAGMENT; TRANSACTIVATOR PROTEIN;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MOUSE; TERATOCARCINOMA; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEOPLASM; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; FIBRONECTINS; GENE PRODUCTS, TAT; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; MICE; ORGAN SPECIFICITY; RECOMBINANT FUSION PROTEINS; TERATOCARCINOMA; TREATMENT OUTCOME; VACCINES, DNA;

EID: 0036074754     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc025517+     Document Type: Article

References (48)

1. Use of isogenic human cancer cells for high-throughput screening and drug discovery
2. Elucidation of the mechanism enabling tumor selective prodrug monotherapy
3. Haemodynamic and transport barriers to the treatment of solid tumours
4. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumours: Significance of elevated interstitial pressure
5. Delivery of molecular and cellular medicine to solid tumors
6. Hematologic malignancies
7. Biopharmaceutical benchmarks
8. Designer genes: Recombinant antibody fragments for biological imaging
9. Increased affinity leads to improved selective tumour delivery of scFv antibodies
10. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier
11. Antibody-directed targeting of the vasculature of solid tumors
12. Antibody-based targeting of angiogenesis
13. Angiogenesis in cancer, vascular, rheumathoid and other disease
14. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis
15. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
16. Increased binding affinity and valence of recombinnat antibody fragments lead to improved targeting of tumoral angiogenesis
17. A high affinity human antibody that targets tumoural blood vessels
18. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment
19. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumours in mice
20. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to the neo-vasculature
21. Enhancement of the antitumor properties of Interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
22. Cellular uptake of the tat protein from human immunodeficiency virus
23. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein
24. Endocytosis and targeting of exogenous HIV-1 Tat
25. The trans-activator gene of HTLV-III is essential for virus replication
26. Regulation of HIV-1 gene expression by the transactivator protein Tat
27. Truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
28. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells
29. In vivo protein transduction: Delivery of a biologically active protein into the mouse
30. Messenger proteins: Homeoproteins, TAT and others
31. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors
32. Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy
33. Alanine substitutions in calmodulin binding peptides result in unexpected affinity enhancement
34. Design and use of a phage-display library: Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel
35. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin
36. Efficient one-step direct labeling of recombinant antibodies with technetium-99m
37. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide
38. Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine
39. Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris
40. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis
41. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin
42. Trojan peptides: The penetratin system for intracellular delivery
43. Identifcation of D-peptide ligands through mirror-image phage display
44. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells
45. Transduction of full-length TAT fusion proteins into mammalian cell: TAT-p27Kip1 induces cell migration
46. Transduction of Cu, Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells
47. Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors